The field of biologic immune modulators is currently mushrooming at a dizzying pace. Although most of these biologics are tested and approved for one or a few indications, their unanticipated side effects and off-label use have contributed significantly to our understanding of basic immune mechanisms, the involvement of cytokines in several apparently nonimmunologic diseases, and the importance of compartmentalized immune responses. In this review we attempt to give a bird's-eye view of the major biologics and to highlight insights and implications derived from their secondary effects and adverse reactions. (J Allergy Clin Immunol 2017;139:1445-56.) Key words: Biologics, biologic response modifiers, immune dysfunction, infection, autoimmunity, immunodeficiency
There have been several milestones in the field of immunology over the past decade. Taking the bird's-eye view, one can divide these developments into 2 categories: understanding the genetic and molecular basis of many immune-related diseases and the development of therapeutics aimed at manipulating specific molecules in the immune pathways. Both venues have challenged some long-held assumptions about the immune system. Although most models and paradigms of the immune response are portrayed by necessity as a linear sequence of events, there is a need for a multidimensional model showing the multiple layers of interactions of seemingly separate systems. For example, until recently, the innate and adaptive immune systems were considered independent of each other. Clearly, this is not the case because now it is obvious that there is constant interaction between the 2 systems. This becomes even more multidimensional when one adds the interaction of these 2 systems with innate lymphoid cells and their products. 1, 2 This understanding is mirrored or confirmed by some of the unanticipated consequences of biological response modifiers (BRMs). Another concept gaining recent traction is compartmentalization of the immune response; this is also mirrored by the apparent paradoxical effects of BRMs on, for example, skin versus joints. 3 Finally, the literature is replete with examples of paradoxical responses to any given biologic; for example, TNF antagonists have been reported to help certain autoimmune diseases while exacerbating others. Even more astonishingly, a TNF antagonist might be beneficial in patients with inflammatory bowel disease (IBD) but might exacerbate the disease in those with spondyloarthropathy. 4 To put the adverse effects of biologics in perspective, one can turn to experiments of nature. It is now well established that mutations along the IL-12/IFN-g pathway result in increased susceptibility to atypical mycobacterial infections. Browne and Holland 5 found that autoantibodies directed along the IL-12/IFN-g pathway can mimic the naturally occurring disease, resulting in significant susceptibility to mycobacterial infections. Hence one wonders whether a biologic directed against IL-12 or IL-12 receptor might result in a similar clinical picture. Indeed, the overlap of autoimmunity and immunodeficiency is now well established 1 ; as we shall see below, the biologics used for treatment of autoimmune disease can also significantly disrupt immune homeostasis.
This review is designed to summarize the adverse effects, both anticipated and unanticipated, of commonly used BRMs and to highlight some of the insights into the immune system functioning that were gained by these reactions. Adverse effects to biologics can be divided into 3 main categories: immune stimulation, immune suppression, and disruption of immune homeostasis.
IMMUNE STIMULATION Cytokine release
Temporally, the earliest type of reaction that can occur with biologics, especially on first administration, is an ''immediate'' reaction. Some of these reactions can be anaphylactic/ anaphylactoid or caused by immune complex formation. A subset of such reactions might be due to massive cytokine release. Commonly reported symptoms include skin rashes, fatigue, fever, chills, myalgia, headaches, nausea, and diarrhea. These are associated with release of proinflammatory cytokines, including IL-1b, TNF-a, IFN-b, IFN-g, IL-6, and IL-8. 6 This is the consequence of activation of various immune cells, including macrophages, monocytes, lymphocytes, and natural killer cells. 7 The mechanism of action can include direct activation through receptor stimulation, antibody-dependent cell-mediated cytotoxicity, complement-mediated cytotoxicity, or apoptosis. One such reaction is associated with muromonab, which is used for acute transplant rejection. Muromonab is directed against CD3, which is part of the signaling complex associated with the Tcell receptor. Muromonab leads to activation of T cells and release of cytokines into the circulation. 8 Rituximab, an mAb against CD20 that is expressed on B cells, mediates antibodydependent cell-mediated cytotoxicity of B cells, resulting in cytokine release, 9 confirming basic studies suggesting that B cells, like T cells, can be a major source of cytokines. 10, 11 For some mAbs there might be a ''first-exposure effect'' in which the reaction wanes with subsequent exposure because of a desensitizing or depleting consequence of the first therapy. 12 An extreme example of cytokine release was seen in the use of TGN1412, an mAb directed against CD28 with the idea that neutralization of the ''second T-cell activation signal'' can result in T-cell anergy, as demonstrated in primate preclinical experiments. When used in human subjects, it turned out to be a T-cell activation agonist. The first trial on 6 patients caused massive activation of lymphocytes, resulting in a cytokine ''storm'' and multiorgan dysfunction requiring transfer to the intensive care unit. 13, 14 This incident is a stark example of the perils of translating animal data, including data from primates, to human subjects.
Prolonged survival of activated lymphocytes
Ipilimumab is an anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) mAb that blocks binding of CTLA-4 to CD80/CD86, thus blocking inhibitory signals to exhausted T cells 15 and resulting in sustained T-cell activation that in this case is the explicit rationale behind its use. Ipilimumab is approved for the treatment of metastatic melanoma. 16, 17 The idea of using such an antibody originally came from mutant mice but was probably re-enforced by identification of the clinical phenotype of CTLA-4 haploinsufficiency in human subjects. Such patients have massive lymphadenopathy caused by the sustained proliferation of activated T cells. Variants in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, primary biliary cirrhosis, and other autoimmune diseases. Given these associated diseases in CTLA-4 haploinsufficiency, it is not surprising that autoimmune diseases were seen in patients given ipilimumab, including skin rashes, inflammatory colitis, hypophysitis, increased liver function tests, and myocarditis. 16, [18] [19] [20] Autoimmunity as a side effect of biologics is very well illustrated by the recent introduction of other checkpoint blockade therapy for malignancies. Pembrolizumab and nivolumab bind to programmed cell death protein 1 (PD-1), thus inhibiting apoptosis of T cells, including regulatory T (Treg) cells, and were introduced to enhance immune responses against tumors. 20 Early results indicate that pembrolizumab and nivolumab are effective against some tumors. However, by virtue of sustaining T-cell activation, similar to ipilimumab, they seem to be associated with the induction or exacerbation of several autoimmune diseases. In the case of ipilimumab, pembrolizumab, and nivolumab, the autoimmune disease activation was expected and confirmed the preclinical understanding of the role of Treg cells and reenforced the importance of ''turning off'' any given immune response at the appropriate timepoint. [21] [22] [23] Another biologic that has been shown to target Treg cells, mogamulizumab, 24 also carries similar autoimmune side effects, including StevensJohnsons syndrome 25 and graft-versus-host disease. 24 Together, these findings emphasize that peripheral tolerance is an ongoing process, even in adults.
IMMUNE SUPPRESSION
Unlike the biologics mentioned above that activate the immune system, whether by design or accident, most of the biologics currently available are directed against turning off an immune response in patients with diseases such as rheumatoid arthritis (RA) or psoriasis, which are clearly associated with an overactive autoimmune response. As one would expect, although turning off an immune response is beneficial in patients with autoimmunity, it might increase susceptibility to infections. Indeed, this has turned out to be the case. It is almost impossible to list all the infections that have been reported with each biologic, but we have attempted to highlight the most commonly reported infections in Table I . 5, 8, 9, 13, 16, [18] [19] [20] 22, 23, These data reflect reports from clinical trials, postmarketing data, and case reports. By necessity, this table is far from complete and should be treated as an overall summary.
Although common infections occur with many of these biologics, some might be most frequently associated with a specific infection, suggesting that there could be a dominant immune pathway involved in the defense against each microorganism. This might not be too surprising given that certain primary immunodeficiencies are associated with selective susceptibility to distinct microorganisms. One example is that patients with deficiencies along the IL-12/IFN-g axis are susceptible to recurrent atypical mycobacterial infections and salmonella but seem to be able to handle most other microorganisms. 26 Lessons learned from patients with primary immunodeficiency also implicate that a certain deficiency might be associated with a certain infection but only in one anatomic compartment. An example is that mutations in Toll-like receptor 3 (TLR3) or UNC93B1 are associated with herpes simplex encephalitis as the dominant infection with little or no peripheral viremia. 73 Infections associated with specific biologics IL-1 has 2 forms, IL-1a and IL-1b, and its activity is normally regulated by the IL-1 receptor antagonist (IL-1RA). IL-1 production is regulated through inflammasome formation in innate immune cells, such as macrophages and neutrophils, during infection; it can enhance effector functions of innate immune cells, B cells, and CD4
1 cells. 74 It is a critical player in both autoimmune and autoinflammatory conditions, such as RA and the periodic fever syndromes, respectively.
There are currently 3 approved anti-IL-1 biologics: anakinra, canakinumab, and rilonacept. 27, 74, 75 Anakinra is a recombinant human IL-1 receptor antagonist that blocks IL-1a and IL-1b activity by competitively binding to the IL-1 receptor type I. Canakinumab is a human anti-IL-1b mAb (IgG 1 ). It neutralizes IL-1 by competing for binding to IL-1RI. Rilonacept is a human dimeric fusion protein, which contains the extracellular domain of both IL-1 receptor components, IL-1RI and IL-1 receptor No longer available
9,37-40 
General infectious issues

Specific infectious risk
Anti-CD52 (alemtuzumab) accessory protein, and has a much higher affinity for IL-1b compared with IL-1a.
Despite its significant position in the immune response, anti-IL-1 therapy has been relatively safe. The most prevalent infectious events are common bacterial and viral infections, and there is little or no increased risk of opportunistic infections with the use of anakinra. 27 Canakinumab, which has a longer half-life compared with anakinra, is associated with a slightly higher rate of common infections. 75, 76 Interestingly, anakinra seems to help control hyperinflammation without worsening active Items in boldface are issues listed as warnings or precautions in product inserts. aHUS, Atypical hemolytic-uremic syndrome; APRIL, a proliferation-inducing ligand; AS, ankylosing spondylitis; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; EMA, European Medicines Agency; FDA, US Food and Drug Administration; GPA, granulomatosis with polyangiitis; HBV, hepatitis virus B; HCV, hepatitis virus C; HL, Hodgkin lymphoma; HNSCC, head and neck squamous cell carcinoma; HSV, herpes simplex virus; ITP, immune thrombocytopenia; MS, multiple sclerosis; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; PD-1, Programmed cell death protein 1; PJIA, polyarticular juvenile idiopathic arthritis; PJP, Pneumocystis jirovecii pneumonia; PNA, pneumonia; PNH, paroxysmal nocturnal hemoglobinuria; PTLD, posttransplantation lymphoproliferative disease; RCC, renal cell carcinoma; SJIA, systemic juvenile idiopathic arthritis; SLE, systemic lupus erythematosus; TACL, Transmembrane activator and CAML interactor; TB, tuberculosis; T1DM, type I diabetes mellitus; UC, ulcerative colitis; URI, upper respiratory tract infection; UTI, urinary tract infection; VZV, varicella zoster virus.
infections in patients with hidradenitis suppurativa, IBD, or chronic granulomatous disease. 27 These findings suggest that IL-1-activated pathways might be more important in the homeostasis of inflammation compared with infection control. Indeed, anakinra has been used extensively in a wide spectrum of diseases (most of which are off-label uses). As summarized in Table II , the beneficial effects of anakinra in patients with these diseases sheds light on the role of immune-mediated inflammation in diseases that hitherto might not have been thought to be related to immune dysfunction. 27 IL-12 is part of a heterodimeric cytokine family and consists of 2 chains: IL-12p35 and IL-12p40. IL-12p40 is a target of ustekinumab, which is approved for the treatment of psoriasis and severe IBD. [77] [78] [79] IL-12p40 is a subunit for both IL-12 and IL-23. As mentioned above, Mendelian susceptibility to mycobacterial disease is a primary immunodeficiency associated with IL12B and IL12RB1 mutations among others. 80 Although there were higher rates of common upper respiratory tract infections and nasopharyngitis in ustekinumab trials, there was not an increased susceptibility to the infections associated with Mendelian susceptibility to mycobacterial disease. 28, 29 This is probably because the IL-12 inhibition by ustekinumab is not complete and the IFN-g pathway is still intact.
Abatacept is a fusion of the extracellular domain of CTLA-4 to an IgG 1 Fc region. It binds to CD80/CD86 with higher affinity than CD28, thus nullifying the ''second signal'' needed for Tcell activation and resulting in T-cell anergy. Types of infections associated with abatacept include sinusitis, nasopharyngitis, bronchitis, urinary tract infection, gastroenteritis, pneumonia, cellulitis, pyelonephritis, and diverticulitis. 30, 81, 82 Specific associated infections include Candida species, mycobacteria, herpes simplex, influenza, herpes zoster, Aspergillus species, and histoplasma. 31, 82 However, meta-analysis of abatacept trials showed no significant increase in serious and total infections. 82, 83 Belatacept, a fusion molecule similar to abatacept but with higher CD80/CD86 avidity, is approved for EBV-seropositive kidney transplant rejection. [32] [33] [34] Adverse reactions reported include nasopharyngitis, cytomegalovirus, mycobacteria, fungi, progressive multifocal leukoencephalopathy (PML), and polyomavirus nephropathy. [32] [33] [34] [35] The different affinity of CD28 and CTLA-4 to CD80/CD86 and the use of belatacept because of its higher avidity bring to life basic immunologic principles that have been theoretical until the dawn of the era of biologicals.
Alemtuzumab is a humanized IgG 1 mAb that binds the CD52 antigen expressed by most human mononuclear cells and is approved for chronic lymphocytic leukemia and multiple sclerosis. Because of expression of the target molecule on lymphocytes, monocytes, dendritic cells, and the male genital tract, alemtuzumab can cause significant cellular immunodeficiency. Severe and lethal infections, including tuberculosis reactivation, systemic viral infections, and invasive systemic fungal infections, have been reported. Infections occur in 30% to 97% of patients. 36 B cells play a major role in autoimmune conditions. In addition to producing antibodies, B cells also secrete cytokines and act as antigen-presenting cells. 84 As such, B cells have been targeted for therapy of autoimmune disorders. Rituximab, the anti-CD20 therapy mentioned above, has shown transient hypogammaglobulinemia with average B-cell recovery up to 9 months after initial dosing. 85, 86 With ongoing treatment, there appears to be a risk of delayed recovery of B cells associated with significant hypogammaglobulinemia and infectious risk. [37] [38] [39] [40] Atacicept, a fusion protein of the transmembrane activator and CAML interactor receptor (TACI) and IgG Fc, binds Blys (also knowns as B-cell activating factor, BAFF) and a proliferation-inducing ligand (which is still in clinical trials). It is associated with increased susceptibility to Haemophilus influenzae, Legionella species, and Klebsiella species infections, some of which were fatal. 41, 42 TNF-a is induced by pathogen-associated molecular patterns and is part of the inflammatory cascade. Although it was known that TNF-a is important in the defense against mycobacterial infection (resulting in the development of granulomas), it was not until TNF antagonists were used in human subjects that it became clear that TNF-a plays a pivotal role in granuloma maintenance. 87, 88 The reactivation of tuberculosis by TNF antagonists was an unanticipated finding. In addition to mycobacterial infections, other infections are associated with anti-TNF-a therapy, including Pneumocystis jirovecii, Listeria species, Legionella species, coccidioidomycosis, Candida species, Histoplasma species, Aspergillus species, and reactivation of hepatitis B. [89] [90] [91] Increased incidence of certain infections, especially fungal infections, is dependent on the prevalent organism in the geographic residence of the patient. 43 Along with IL-1 and TNF-a, IL-6 is considered an early innate signaling cytokine. Tocilizumab, an anti-IL-6 receptor mAb, is approved for RA and systemic onset juvenile arthritis. Similar to anti-TNF-a therapy, tocilizumab has been associated with mycobacterial infection reactivation. 44, 92 Interestingly, blockade of IL-6 by tocilizumab, similar to anti-IL-1 therapy, seems to be beneficial in the treatment of hyperinflammatory disease and the cytokine storm. 93 Deficiencies in the terminal components of complement (C5-C9) are associated with recurrent invasive Neisseria species infections. 94 Eculizumab is an mAb that binds with high affinity to complement protein C5, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9. 95, 96 Eculizumab is approved for treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. 95, 96 Therefore a theoretical concern is an increased susceptibility to neisserial infections. Although patients were given meningococcal vaccine before the antibody therapy, during clinical trials, 2 patients had Neisseria species-related meningitis, thus reproducing the natural deficiencies of terminal complement components. 45 IL-17A is important to the immune response to both extracellular bacterial and fungal infections. At least 2 primary immunodeficiency diseases are associated with deficiencies in IL-17: chronic mucocutaneous candidiasis and hyper-IgE syndrome. RA, psoriasis, and multiple sclerosis are associated with increased IL-17 levels. Secukinumab is an anti-IL-17A mAb that is approved for psoriasis and ankylosing spondylitis. 46, 97, 98 As expected, secukinumab is associated with an increase in candida infections, herpes virus, tinea pedis, and perianal dermatophytosis. 47, 48, 99 Cancer Multiple biologics have been associated with an increased risk of cancer. Ustekinumab has been associated with nonmelanoma skin cancer. 49 Belatacept, discussed above, is associated with nonmelanoma skin cancer and lymphoproliferative disease. 32, 33 There are multiple lines of clinical data on the risk of lymphoma, leukemia, and solid malignancies with the use of TNF inhibitors. 100 However, the true association is controversial because covariants, including the underlying disease process and other concomitant immunosuppressive therapy, obscure the data. 100 
DISRUPTION OF IMMUNE HOMEOSTASIS Autoimmunity
TNF inhibitor therapy has been associated with cutaneous vasculitis and lupus-like syndromes that resolve on discontinuation of the inhibitor therapy. 50 Other autoimmune phenomena associated with TNF inhibitors include cutaneous psoriasis, sarcoidosis, antiphospholipid syndrome, uveitis, interstitial lung disease, dermatomyositis, polymyositis, demyelinating disease, peripheral neuropathies, and autoimmune hepatitis. [51] [52] [53] [54] [55] [56] [57] 101 These complications occurred with both anti-TNF mAbs and the TNF receptor fusion protein etanercept, indicating that these reactions represent a drug class effect of TNF blockers. Additionally, atacicept is a recombinant fusion protein containing the extracellular TACI receptor and IgG 1 Fc. Atacicept targets Blys and a proliferation-inducing ligand inhibiting their activities (APRIL). In trials for multiple sclerosis, atacicept was associated with an unexpected worsening of central nervous system (CNS) lesions. 102 Additionally, secukinumab, an anti-IL-17A mAb, was associated with Crohn disease. 46 
Hypersensitivity
Hypersensitivity is an expected risk of BRMs because these molecules can serve as antigens, even if they are fully humanized, given the development of anti-idiotype antibodies. To stay consistent with the theme of this review, we will not cover typical anaphylactic or anaphylactoid reactions to biologics because these have been covered extensively recently. 103 Rather, here we will focus on 2 unique hypersensitivity reactions occurring with BRMs that have further informed our understanding of hypersensitivity reactions.
One interesting story of hypersensitivity to BRMs unfolded with cetuximab, an anti-epidermal growth factor receptor mAb. Anaphylactic reactions to cetuximab occurred during the first infusion in about 5% of patients. This was determined to be due to preformed antibodies against the galactose-a-1,3-galactose. 104, 105 This sugar moiety occurs as a posttranslational modification of cetuximab and is expressed in all tissues of mammals except human subjects and old world monkeys. Sensitization appears to be linked to a bite by the lone star tick. 106 Hypersensitivity reactions to radiocontrast media have been associated with rIL-2 therapy in cancer patients. 58 These reactions occurred in 28% of patients who had previously received IL-2 together with radiocontrast media. The hypersensitivity reactions occurred on subsequent exposures to radiocontrast media. It is likely this phenomena occurs through an adjuvant-like mechanism.
COMPARTMENTALIZATION
An important concept for immune system function is the idea of compartmentalization. Perhaps this is not a novel idea because it has been known for quite some time that certain organs are ''immune privileged.'' More recently, however, this concept has been modified to suggest that the local microenvironment of any given organ can modify the quality and/or quantity of an immune response. For example, immune responses to mucosal exposure might be different than responses to parenteral administration. The concept of immune compartmentalization is evident in differential organ responsiveness to certain biologics. For example, the response to rituximab in patients with some autoimmune diseases (immune thrombocytopenic purpura, Graves disease, and pemphigus vulgaris) correlated with the decrease in autoantibody titers. In patients with other diseases (eg, systemic lupus erythematosus and RA), however, a significant clinical response did not necessarily correlate with the decrease in autoantibody titers, suggesting that B cells contribute to the disease through mechanisms other than (or in addition to) autoantibody production or that rituximab might have hitherto unidentified immune effects other than its binding to CD20. It is possible that localized effects, such as cell-to-cell communication, might be more important than the diffuse effects of antibody production. In an open-label pilot study, 107 rituximab was used for atopic eczema. By using the Eczema Area and Severity Index, all patients had a significant reduction in skin symptoms. However, allergen-specific IgE levels were not significantly decreased, but cutaneous B-cell numbers were reduced by 50%. Similar to the results with rheumatologic diseases, it appears that local B cells might play a significant role in atopic dermatitis apart from IgE.
TNF-a antagonists
Although TNF inhibitors are indicated for psoriatic arthritis, they have been associated with exacerbation of numerous skin disorders, including cutaneous psoriasis, as well as cutaneous lupus, cutaneous vasculitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, eosinophilic fasciitis, and atopic dermatitis. 3, 59, 60 Although there is general agreement that TNF-a is an inflammatory mediator, these paradoxical effects of TNF antagonists suggest that TNF might be detrimental in the joints but protective in the skin.
IL-6
Tocilizumab, which targets IL-6 receptor, seems to have a predilection for hepatic toxicity. Increased levels of liver enzymes, as well as increased plasma lipid levels, are relatively common side effects. 61 Although the exact mechanism for the induction of transaminitis is not yet known, IL-6 is important for hepatocyte homeostasis and has been linked to both hepatic regeneration and metabolic function. Additionally, IL-6 is believed to be important in promoting liver tumors. 108 
Integrins
Biologics targeting integrins have underscored the important role of integrins in tissue-specific responses. a4b7 Integrin is expressed on gut-associated lymphoid tissue and binds mucosal addressin cell-adhesion molecule 1 (MAdCAM-1). Vedolizumab, an anti-a4b7 integrin mAb that targets intestine-homing lymphocytes, is approved for the treatment of IBD. 62, 109 Secondary to this selectivity, there were minor increases in gastrointestinal infections. 62 Natalizumab, an anti-a4 integrin antibody approved for the treatment of multiple sclerosis and Crohn disease, is associated with PML, suggesting there is a role of adhesion molecules in the control of the JC polyomavirus infection. 63 Natalizumab has also been associated with varicella zoster and herpes simplex infections of the CNS. 64 Efalizumab, a recombinant anti-aLb2 (LFA-1) antibody, was withdrawn from the market in 2009 because of 3 fatal cases of PML. 65 It is assumed that the blocking effect of these integrin antibodies leads to impaired trafficking of immune cells into the CNS, leading to the increased risk of infection. These were all unexpected findings because it was thought that the blood-brain barrier blocks lymphocyte migration to the brain. These side effects suggest that peripheral lymphocytes might use adhesion molecules to enter the CNS, where they keep JC polyomaviruses, if not other viruses as well, at bay.
IL-2
rIL-2 used in cancer therapy has multiple immunostimulatory effects, including effects on T cells, natural killer cells, monocytes, and B cells. Many of its reported toxicities stem from capillary leak-associated changes. 66, 67 Indeed, high-dose IL-2 is associated with capillary leak syndrome, which differs from the idiopathic capillary leak syndrome (Clarkson syndrome) in that pulmonary edema is not a feature of Clarkson syndrome except in the recovery phase. It appears that IL-2 increases endothelial cell permeability in most organs, whereas the mechanisms inducing Clarkson syndrome (which are still unknown) spare pulmonary endothelial cells. 110 Additional toxicities of high-dose IL-2 include flu-like illness, nausea, diarrhea, skin rashes, hypothyroidism, altered mental status, cytopenias, coagulopathy, hyperbilirubinemia, elevated transaminase levels, hypoalbuminemia, and acid/base and electrolyte imbalances. IL-12 administered to patients in a phase II trial resulted in serious adverse events that involved increased transaminase levels, hyperbilirubinemia, cytopenias, severe fatigue, dyspnea, and stomatitis. 69, 70 These wide-ranging effects suggest that organ specificity, at least for cytokine effects, might be dose dependent and might not be different from the multiorgan disease seen in patients with certain gain-of-function mutations. 111, 112 It is worth noting that the generalized toxicities of IL-2 are dose dependent. Indeed, low-dose IL-2 therapy has been tried with the aim of targeting Treg cells. Treg cells constitutively express the IL-2 receptor a chain (CD25) on their surfaces. It is thought that low-dose IL-2 therapy might result in preferential activation of Treg cells, which might be beneficial in autoimmune diseases. It remains to be seen whether this strategy will be effective. 113 
CLARIFYING THE SPECTRUM OF DISEASE Asthma
The use of biologics is also prompting rethinking the spectrum of disease subsets (endotypes) based on molecular markers. 114 Studies with TNF antagonists in asthmatic patients 115 did not reveal a major therapeutic benefit, and most clinical trials with TNF antagonists are currently on hold. This might be premature because, as indicated by Brightling et al, 116 there could be a subset of asthmatic patients who might benefit from TNF neutralization, including those with T H 17-high or neutrophilic asthma. There is a need for measuring levels of various cytokines in blood, sputum, and bronchoalveolar lavage fluid with the hope of targeting biologic therapy to the dominant cytokine. One can predict that the future of biologics will involve custom-tailored biologic therapy depending on the spectrum of biomarkers identified in subsets of a given disease. The need for this is best illustrated by anti-IL-5 therapy in asthmatic patients. Currently, 2 anti-IL-5 biologics, mepolizumab and reslizumab, are approved for use in patients with severe and uncontrolled asthma. Initial studies of mepolizumab in asthmatic patients did not show a significant effect. 117 It was not until patients were endotyped based on their eosinophil status that subsequent studies showed that this medication could have a very significant effect in treating appropriately selected asthmatic patients.
118-120
RA
Several patient variables have been associated with differing responses to the array of biologic therapies in patients with RA. Some variables are modifiable, such as obesity and smoking, although others are more inherent to the patient, including disease activity, quality of life scores, serotype, genetics, and cytokine levels. 121 
Psoriasis and ankylosing spondylitis
Studies in patients with psoriasis and ankylosing spondylitis demonstrate that additional disease states predict response to particular biologics. For instance, in cases of severe arthritis, severe cutaneous involvement, or the comorbidities of anterior uveitis or IBD, anti-TNF-a therapy is the preferred choice. 122 
IBD
A number of patient variables have been associated with response to biologics in both patients with ulcerative colitis and those with Crohn disease and include inflammatory markers, disease duration, smoking status, isolated ileitis, isolated colitis, age, previous exposure to biologic agents, and immunosuppressant drugs. 123 Additionally, a number of genetic polymorphisms have been associated with response to anti-TNF therapy in both patients with ulcerative colitis and those with Crohn disease. 124 
Chronic rhinosinusitis
Multiple biologics have been studied in patients with chronic rhinosinusitis. Most of these have targeted chronic rhinosinusitis with nasal polyposis because this subtype is highly associated with T H 2-type inflammation. Multiple studies have shown effectiveness for anti-IL-5 (mepolizumab and reslizumab), anti-IgE (omalizumab), and anti-IL-4/IL-13 (dupilumab) in the polyposis subtype. 125 Of note, the anti-IL-5 therapies correlated with biomarker levels, including serum IL-5Ra, eosinophil cationic protein, and peripheral eosinophil levels. 125 
CONCLUSION
We are well beyond the dawn of the age of biologics. The approval of numerous biologic therapies for use in patients with immune disorders is approaching a dizzying rate. Not only does this new reality provide opportunity to further our knowledge of the human immune system, but it also illustrates the need for a clinical immunologist who can navigate the nonlinear interactions of various arms of the immune system. Indeed, many biologics are used in nonimmunologic disciplines; this might result in a delayed recognition of unintended consequences. This review demonstrates that biologics have reinforced some basic immunology learned in in vitro and animal studies and negated others. Through immunostimulatory effects of these therapies, we have witnessed adverse events of cytokine release and induction of autoimmunity. Their use has also reinforced the knowledge of immune-suppressed states regarding immunodeficiency in both human disease and animal models and further delineated parts of the immune system that help protect against particular infections or cancer. Additionally, the observed effects of biologics indicate that induced immune imbalance or disruption of immune homeostasis might lead to ''hypersensitivity'' to self-antigens or foreign antigens. Certain immune molecules appear to play more of a role in particular tissues thus emphasizing the importance of immune system compartmentalization. The use of biologics is also helping uncover endotypes of disease. A schematic overview of various biologics discussed and their site of action is depicted in Fig 1. We hope this review provides an overview of the lessons learned from the use of clinical biologics and a glimpse of the type of insights that might lie ahead. Integrin; a4b7, a4b7 integrin; alb2, alb2 integrin; APC, antigen-presenting cell; BAFF, B-cell activating factor; BCMA, B-cell maturation antigen; ICAM-1, intercellular adhesion molecule 1; IL-2R, IL-2 receptor; MAdCAM-1, mucosal vascular addressin cell adhesion molecule 1; TACI, transmembrane activator and CAML interactor; VCAM-1, vascular cell adhesion molecule 1.
